PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)

L Adès; J Watts; A Radinoff; M.A Sangerman; M Cerrano; P.F Lopez; J Zeidner; M.D Campelo; C Graux; J Liesveld; D Selleslag; N Tzvetkov; R.J Fram; D Zhao; J Bell; S Friedlander; D.V Faller; M.A Sekeres

doi:10.1016/j.htct.2020.10.475

Back

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)

Journal article

Open access

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)

L Adès, J Watts, A Radinoff, M.A Sangerman, M Cerrano, P.F Lopez, J Zeidner, M.D Campelo, C Graux, J Liesveld, …

Hematology, Transfusion and Cell Therapy, Vol.42, pp.285-286

2020-11

DOI: https://doi.org/10.1016/j.htct.2020.10.475

Files and links (1)

url

https://doi.org/10.1016/j.htct.2020.10.475View

Published (Version of record) Open

Metrics

5 Record Views

Details

Title: PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
Creators: L Adès - Hôpital Saint-Louis
J Watts - University of Miami
A Radinoff - University Hospital Sveti Ivan Rislki, Sofia, Bulgaria
M.A Sangerman - Institut d'Investigació Biomédica de Bellvitge
M Cerrano - University of Turin
P.F Lopez - Hospital General Universitario Gregorio Marañón
J Zeidner - University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, United States
M.D Campelo - Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain
C Graux - UCLouvain
J Liesveld - University of Rochester
D Selleslag - AZ Sint-Jan
N Tzvetkov - MHAT Dr. Georgi Stranski, Clinic of Haematology, Pleven, Bulgaria
R.J Fram - Millennium Pharmaceuticals, Inc., Cambridge, United States, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
D Zhao - Millennium Pharmaceuticals, Inc., Cambridge, United States, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
J Bell - Takeda
S Friedlander - Millennium Pharmaceuticals, Inc., Cambridge, United States, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
D.V Faller - Millennium Pharmaceuticals, Inc., Cambridge, United States, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
M.A Sekeres - Hôpital Saint-Louis
Publication Details: Hematology, Transfusion and Cell Therapy, Vol.42, pp.285-286
Publisher: Elsevier Editora Ltda
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031713857502976